Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy (Q35641623)

9 August 2017

1 reference

title

Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy (English)

1 reference

9 August 2017

1 reference

1 reference

Stephen M Setter

1

1 reference

9 August 2017

Jason L Iltz

series ordinal

2

1 reference

9 August 2017

Jason Thams

series ordinal

3

1 reference

9 August 2017

R Keith Campbell

series ordinal

4

1 reference

9 August 2017

language of work or name

1 reference

1 December 2003

1 reference

9 August 2017

Clinical Therapeutics

1 reference

9 August 2017

25

1 reference

9 August 2017

12

1 reference

9 August 2017

2991-3026

1 reference

Insulin resistance, impaired glucose tolerance and non-insulin-dependent diabetes, pathologic mechanisms and treatment: current status and therapeutic possibilities.

9 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Economic costs of diabetes in the US in 2002.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Insulin resistance, diabetes, and the adipocyte.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Cardiovascular risk continuum: implications of insulin resistance and diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Vascular complications in diabetes and their prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Oral antihyperglycemic therapy for type 2 diabetes: scientific review

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Worldwide experience of metformin as an effective glucose-lowering agent: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Improving management of type 2 diabetes mellitus: 2. Biguanides

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Type 2 diabetes management: a comprehensive clinical review of oral medications

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

An overview of metformin in the treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Traditional plant medicines as treatments for diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Role of AMP-activated protein kinase in mechanism of metformin action

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Metabolic effects of metformin in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

1 reference

7 January 2021

Cellular mechanism of action of metformin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

A risk-benefit assessment of metformin in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

1 reference

7 January 2021

Metformin Causes a Reduction in Basal and Post-venous Occlusion Plasminogen Activator Inhibitor-1 in Type 2 Diabetic Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Effect of combination glipizide GITS/metformin on fibrinolytic and metabolic parameters in poorly controlled type 2 diabetic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

The effect of metformin on adipose tissue metabolism and peripheral blood flow in subjects with NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Improved endothelial function with metformin in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Treatment for the procoagulant state in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Clinical pharmacokinetics of metformin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Food intake and dosage level, but not tablet vs solution dosage form, affect the absorption of metformin HCl in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Metformin kinetics in healthy subjects and in patients with diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Disposition of metformin (N,N-dimethylbiguanide) in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Re-evaluation of a biguanide, metformin: mechanism of action and tolerability

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Transfer of metformin into human milk

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Transfer of metformin into human milk

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Metformin hydrochloride: an antihyperglycemic agent.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Reduction of metformin renal tubular secretion by cimetidine in man

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Drug/drug and drug/disease interactions and diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Antihyperglycaemic agents. Drug interactions of clinical importance

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

The influence of Guar gum on absorption of metformin from the gut in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

The influence of dimethylbiguanide on phenprocoumon elimination and its mode of action. A drug interaction study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Metformin: a new oral biguanide

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Metformin-associated nonketotic metabolic acidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Lactic acidosis rates in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Oral hypoglycaemic agents in 118 diabetic pregnancies.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Troglitazone: a review of its use in the management of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Comparison of tolbutamide and metformin in elderly diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Prospective comparative study in NIDDM patients of metformin and glibenclamide with special reference to lipid profiles

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Comparison of chlorpropamide and metformin treatment on weight and blood-glucose response of uncontrolled obese diabetics.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Efficacy of metformin in the treatment of NIDDM. Meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. U.K. Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Low dose metformin in the treatment of type II non-insulin-dependent diabetes: clinical and metabolic evaluations

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Repaglinide versus metformin in combination with bedtime NPH insulin in patients with type 2 diabetes established on insulin/metformin combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Comparison of acarbose and metformin in patients with Type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

A comparison of preconstituted, fixed combinations of low-dose glyburide plus metformin versus high-dose glyburide alone in the treatment of type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Glyburide/metformin combination product is safe and efficacious in patients with type 2 diabetes failing sulphonylurea therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance) in Type 2 diabetic patients inadequately controlled on metformin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

The cost to health plans of poor glycemic control

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Potential short-term economic benefits of improved glycemic control: a managed care perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Impact of dosage frequency on patient compliance.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

Utilization of oral hypoglycemic agents in a drug-insured U.S. population

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990089-0

7 January 2021

10.1016/S0149-2918(03)90089-0

Identifiers

DOI

1 reference

9 August 2017

1 reference